GLRA
ALDR

Gerald L. Ray & Associates’s Alder Biopharmaceuticals ALDR Stock Holding History

Gerald L. Ray & Associates’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-9,100
Closed -$298K – 325
2016
Q3 		$298K Buy
+9,100
New +$277K 0.04% 251

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Gerald L. Ray & Associates's ALDR Position: Q4 2016 in Review

Gerald L. Ray & Associates sold out of Alder Biopharmaceuticals (ALDR) in Q4 2016, closing a stake of 9,100 shares — an estimated $298K sold.

Gerald L. Ray & Associates first reported a position in ALDR in Q3 2016 and held it in 1 quarter. The position peaked at $298K in Q3 2016. 145 funds tracked by Wall St. Rank hold ALDR as of Q4 2016.

  • Gerald L. Ray & Associates reported no remaining Alder Biopharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Gerald L. Ray & Associates sold 9,100 Alder Biopharmaceuticals shares in Q4 2016, an estimated $298K.
  • Gerald L. Ray & Associates first reported a position in Alder Biopharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Gerald L. Ray & Associates's Alder Biopharmaceuticals position peaked at $298K in Q3 2016.
  • 145 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2016.

Based on Gerald L. Ray & Associates's 13F filing for Q4 2016, filed 7 Feb 2017.